Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin® As First-Line Therapy of Advanced HER-2 Positive Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00093145
• Other study ID #: CA016
• Status: Completed
• Phase: Phase 2
• Start date: June 1, 2004
• Est. completion date: October 1, 2008

Study information

• Verified date: November 2019
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.

Other known NCT identifiers

• NCT00085605

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: October 1, 2008
• Est. primary completion date: October 1, 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed adenocarcinoma of the breast

• Tumor shows 3+ overexpression of the human epidermal growth factor receptor 2 (HER-2)/proto-oncogene by immunohistochemistry assay, or is fluorescence in situ hybridization (FISH)+

• Stage IV disease

• Measurable disease

• At least 3 weeks since prior cytotoxic chemotherapy

• At least 4 weeks since radiotherapy with full recovery

• At least 4 weeks since major surgery with full recovery

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• At least 18 years old

• Absolute neutrophil count (ANC) at least 1.5 x 10^9 cells/L

• Platelets at least 100 x 10^9 cells/L

• Hemoglobin at least 9 g/dL

• Aspartame aminotransferase (AST), alanine aminotransferase (ALT) less than 2.5X upper limit normal

• Alkaline Phosphatase less than 1.5X upper limit normal

• Creatinine less than 1.5 gm/dL

• Normal left ventricular ejection fraction

• Negative pregnancy test

• Agree to use method to avoid pregnancy

• Informed Consent is obtained

Exclusion Criteria:

• Up to one regimen of prior neo-adjuvant or adjuvant chemotherapy is allowed. One year since Taxane and Herceptin treatment.

• Cumulative life-time dose of doxorubicin is greater than 360 mg/m^2

• Concurrent immunotherapy or hormonal therapy

• Parenchymal brain metastases, if present, must be documented to be clinically and radiographically stable for at least 6 months after treatment

• Serious intercurrent medical or psychiatric illness, including serious active infection

• History of congestive heart failure

• History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer

• Patients who have received an investigational drug within the previous 3 weeks

• Patient is currently enrolled in another clinical study receiving investigational therapies

• Pregnant or nursing women

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Albumin-bound paclitaxel
Administered by intravenous infusion.
• Carboplatin
Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
• Herceptin®
Administered by IV infusion

Locations

Country	Name	City	State
United States	Gerogia Cancer Specialist	Atlanta	Georgia
United States	Southwest Regional Cancer Center	Austin	Texas
United States	Florida Cancer Institute	Hudson	Florida
United States	Breastlink Med Group	Long Beach	California
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	University of Pittsburgh Medical Center Magee Womens Hospital	Pittsburgh	Pennsylvania
United States	Rhode Island Hospital	Providence	Rhode Island
United States	Gulf Coast Oncology Associates	Saint Petersburg	Florida
United States	Maine Center for Cancer Medicine and Blood Disorders	Scarborough	Maine
United States	Swedish Medical Center Cancer Institute Research	Seattle	Washington
United States	Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center	Stamford	Connecticut
United States	Lombardi Cancer Center Georgetown University Hospital	Washington	District of Columbia
United States	Washington Hospital Center	Washington	District of Columbia
United States	Palm Beach Cancer Institute	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Country where clinical trial is conducted

United States, 

References & Publications (1)

Conlin AK, Seidman AD, Bach A, Lake D, Dickler M, D'Andrea G, Traina T, Danso M, Brufsky AM, Saleh M, Clawson A, Hudis CA. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response	Percentage of participants who achieved an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. A partial response (PR) is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing, or with the persistence of one or more non-target lesions and/or the maintenance of tumor marker level above the normal limits.	Objective response was evaluated every 2 cycles, up to a maximum of 39 cycles (approximately 39 months)
Secondary	Percentage of Participants With a Total Response	Total response was defined as the percentage of participants with stable disease (SD) for = 16 weeks or complete or partial overall response. Stable disease was defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. Progressive disease is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.	Evaluated every 2 cycles, up to a maximum of 39 cycles.
Secondary	Time to Disease Progression	Time to disease progression was measured from the date of first dose of study drug to the start of disease progression. Patients who did not have disease progression at the end of follow-up were censored at the last known time that the patient was evaluated for progression. Progression is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Time to disease progression was summarized using Kaplan-Meier methods.	Assessed every 2 cycles, up to a maximum of 39 cycles.
Secondary	Duration of Response	Duration of response was evaluated by measuring progression-free survival for participants with a complete response or partial response. Progression-free survival was defined as the time from the first dose of study drug to the start of progression or patient death (whichever occurred first). Participants who did not have progression or were still alive were censored at the last known time the patient was progression free. Patients that initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progression is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.	Assessed every 2 cycles, up to a maximum of 39 cycles.
Secondary	Overall Patient Survival	Overall survival was defined as the time from the day of randomization to patient death (due to any cause), as assessed by post study follow-up on a monthly basis for 3 months and every 3 months. Participants still alive were censored at the last known time that the patient was alive. Patient survival was estimated using Kaplan-Meier methods.	From Day 1 until approximately 44 months.
Secondary	Number of Participants With Adverse Events (AEs)	A Treatment-emergent AE was any AE that began or worsened after the start of study drug through 30 days after the last dose of study drug or end of study whichever is later. A treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above	Day 1 up to 39 cycles